Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients

Inclusion Criteria: * Weight greater than 40 kg (88.2 lbs) * Will be receiving a living-related (1-haplotype-matched donor/recipient) primary kidney allograft * Negative B-cell and T-cell cytotoxic and flow cytometry crossmatch (1-haplotype-matched donor/recipient pairs with a minimum of 1 HLA DR 1A and 1B locus in common and panel-reactive antibodies \[PRA\] of less than 10%) * Normal echocardiogram (ECG) with an ejection fraction of greater than 50% * Received full course of vaccination for hepatitis B virus (HBV), completed at least 6 weeks before transplantation, OR has naturally acquired immunity * Willing to comply with the study visits * Willing to use acceptable forms of contraception Exclusion Criteria: * Previously received or is receiving an organ transplant other than a kidney * Receiving an ABO (blood type) incompatible donor kidney * Human Immunodeficiency Virus (HIV) infected * Antibody positive for hepatitis C virus (HCV) * Surface antigen positive for hepatitis B virus (HBV) * Recipient or donor is positive for tuberculosis (TB), under treatment for suspected TB, or previously exposed to TB (positive Mantoux test) * Current cancer or a history of cancer within the 5 years prior to study entry. Patients who have had successfully treated nonmetastatic basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix are not excluded. * Significant liver disease, defined as having continuously elevated aspartate aminotransferase (AST SGOT) or al…